The present invention relates to dissolvable containers for animal feed micro-ingredients, and methods for using such dissolvable containers to prepare an animal feed mixture. Ingredients required in very small amounts with respect to the rest of the components in an animal feed, i.e., micro-ingredients, can be pre-measured and sealed within the dissolvable containers, which can be made from a water-soluble polymer film, then added to the other feed components when the complete animal feed is being prepared.

The present invention relates to dissolvable containers for animal feed micro-ingredients, and methods for using such dissolvable containers to prepare an animal feed mixture. Ingredients required in very small amounts with respect to the rest of the components in an animal feed, i.e., micro-ingredients, can be pre-measured and sealed within the dissolvable containers, which can be made from a water-soluble polymer film, then added to the other feed components when the complete animal feed is being prepared.

The invention relates to a medicament containing a compound of general formula (I), where R.sub.1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkinyl group, preferably a C.sub.11-C.sub.15 alkyl, alkylene or alkinyl group, particularly a C.sub.11-C.sub.13 alkyl, alkylene or alkinyl group, most preferably a C.sub.13 alkyl group, R.sub.2=independently, a straight or branched C.sub.1-C.sub.8 alkyl, alkylene or alkinyl group, preferably a C.sub.1-C.sub.6 alkyl, alkylene or alkinyl group, in particular a C.sub.2-C.sub.4 alkyl, alkylene or alkinyl group, most preferably a C.sub.3 alkyl group, a —[CH.sub.2—(CH.sub.2)m-O].sub.nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH.sub.2—[CH—(OH)].sub.p[CH.sub.2—R.sub.3]- group, where R.sub.3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

The invention provides, inter alia, methods for modulating DNA sensing pathways and the innate immune responses downstream of such pathways. The invention contemplates methods for down-regulating this pathway and/or the downstream innate immune response. The invention further contemplates methods for up-regulating this pathway and/or the downstream innate immune response.

The invention provides, inter alia, methods for modulating DNA sensing pathways and the innate immune responses downstream of such pathways. The invention contemplates methods for down-regulating this pathway and/or the downstream innate immune response. The invention further contemplates methods for up-regulating this pathway and/or the downstream innate immune response.

An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C.sub.max) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.

Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.

Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.

Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.